Drug Type Small molecule drug |
Synonyms Alendronate/dextran/guanidine, ODX |
Target- |
Mechanism Iron Supplements, Osteoclasts inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC4H15NNaO8P2 |
InChIKeyHZMNHMQPEYMSTG-UHFFFAOYSA-N |
CAS Registry121268-17-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone metastases | Phase 2 | EE | 01 May 2016 | |
Bone metastases | Phase 2 | FI | 01 May 2016 | |
Bone metastases | Phase 2 | LV | 01 May 2016 | |
Bone metastases | Phase 2 | SE | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | EE | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | FI | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | LV | 01 May 2016 | |
Castration-Resistant Prostatic Cancer | Phase 2 | SE | 01 May 2016 | |
Metastatic castration-resistant prostate cancer | Phase 2 | SE | 01 Jan 2015 | |
Prostatic cancer metastatic | Phase 2 | SE | 01 Jan 2015 |
Phase 2 | Castration-Resistant Prostatic Cancer bone alkaline phosphatase (B-ALP) | serum-aminoterminal-propeptide of Type I procollagen (S-P1NP) | serum C-terminal telopeptide | 55 | ODX 3 mg/kg | xykqhlnioy(fbkdokeqdu) = fjvzkksvdh suotyhujek (tpnzgwrcuh ) | - | 01 Mar 2023 | |
ODX 6 mg/kg | xykqhlnioy(fbkdokeqdu) = nyoitjbtmr suotyhujek (tpnzgwrcuh ) |